132 related articles for article (PubMed ID: 33645440)
1. Real life experience with ceftolozane/tazobactam therapy for
Khan S; Phe K; Tam VH
J Chemother; 2021 Dec; 33(8):595-597. PubMed ID: 33645440
[No Abstract] [Full Text] [Related]
2. A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection.
Fernández-Cruz A; Alba N; Semiglia-Chong MA; Padilla B; Rodríguez-Macías G; Kwon M; Cercenado E; Chamorro-de-Vega E; Machado M; Pérez-Lago L; García de Viedma D; Díez Martín JL; Muñoz P
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530598
[TBL] [Abstract][Full Text] [Related]
3. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Bassetti M; Castaldo N; Cattelan A; Mussini C; Righi E; Tascini C; Menichetti F; Mastroianni CM; Tumbarello M; Grossi P; Artioli S; Carannante N; Cipriani L; Coletto D; Russo A; Digaetano M; Losito AR; Peghin M; Capone A; Nicolè S; Vena A;
Int J Antimicrob Agents; 2019 Apr; 53(4):408-415. PubMed ID: 30415002
[TBL] [Abstract][Full Text] [Related]
4. Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study.
Hakeam HA; Askar G; Al Sulaiman K; Mansour R; Al Qahtani MM; Abbara D; Aldhayyan N; Dyab N; Afaneh L; Islami M; Al Duhailib Z
J Infect Public Health; 2022 Oct; 15(10):1081-1088. PubMed ID: 36113401
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
[TBL] [Abstract][Full Text] [Related]
6. Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam.
Monterrubio-Villar J; Rodríguez-Garrido S; Jiménez-Delgado JD
Rev Esp Quimioter; 2018 Aug; 31(4):374-375. PubMed ID: 30014680
[No Abstract] [Full Text] [Related]
7. Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa.
Dinh A; Wyplosz B; Kernéis S; Lebeaux D; Bouchand F; Duran C; Béraud G; Lazaro P; Davido B; Hénard S; Canouï E; Ferry T; Wolff M
Int J Antimicrob Agents; 2017 Jun; 49(6):782-783. PubMed ID: 28412272
[No Abstract] [Full Text] [Related]
8. Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
Balandin B; Ballesteros D; Ruiz de Luna R; López-Vergara L; Pintado V; Sancho-González M; Soriano-Cuesta C; Pérez-Pedrero MJ; Asensio-Martín MJ; Fernández-Simón I; Rodríguez-Serrano D; Silva A; Chicot M; Iranzo R; Martínez-Sagasti F; Royuela A
Int J Antimicrob Agents; 2021 Mar; 57(3):106270. PubMed ID: 33347991
[TBL] [Abstract][Full Text] [Related]
9. Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient.
Aitken SL; Kontoyiannis DP; DePombo AM; Bhatti MM; Tverdek FP; Gettys SC; Nicolau DP; Nunez CA
Pediatr Infect Dis J; 2016 Sep; 35(9):1040-2. PubMed ID: 27254038
[TBL] [Abstract][Full Text] [Related]
10. Ceftolozane/Tazobactam Treatment of Multidrug-resistant Pseudomonas aeruginosa Infections in Children.
Molloy L; Abdulhamid I; Srivastava R; Ang JY
Pediatr Infect Dis J; 2020 May; 39(5):419-420. PubMed ID: 32032173
[TBL] [Abstract][Full Text] [Related]
11. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
12. Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.
Evans SR; Tran TTT; Hujer AM; Hill CB; Hujer KM; Mediavilla JR; Manca C; Domitrovic TN; Perez F; Farmer M; Pitzer KM; Wilson BM; Kreiswirth BN; Patel R; Jacobs MR; Chen L; Fowler VG; Chambers HF; Bonomo RA;
Clin Infect Dis; 2019 May; 68(11):1823-1830. PubMed ID: 30239599
[TBL] [Abstract][Full Text] [Related]
13. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
Giani T; Arena F; Pollini S; Di Pilato V; D'Andrea MM; Henrici De Angelis L; Bassetti M; Rossolini GM;
J Antimicrob Chemother; 2018 Mar; 73(3):664-671. PubMed ID: 29216350
[TBL] [Abstract][Full Text] [Related]
14. Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program.
Stewart A; Roberts JA; Wallis SC; Allworth AM; Legg A; McCarthy KL
Int J Antimicrob Agents; 2018 Jun; 51(6):941-942. PubMed ID: 29471023
[No Abstract] [Full Text] [Related]
15. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
Xipell M; Bodro M; Marco F; Martínez JA; Soriano A
Future Microbiol; 2017 Nov; 12():1323-1326. PubMed ID: 28980834
[TBL] [Abstract][Full Text] [Related]
16. Ceftolozane-Tazobactam Pharmacokinetics during Extracorporeal Membrane Oxygenation in a Lung Transplant Recipient.
Arena F; Marchetti L; Henrici De Angelis L; Maglioni E; Contorni M; Cassetta MI; Novelli A; Rossolini GM
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642936
[No Abstract] [Full Text] [Related]
17. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Johnson MG; Bruno C; Castanheira M; Yu B; Huntington JA; Carmelitano P; Rhee EG; De Anda C; Motyl M
Int J Antimicrob Agents; 2021 Mar; 57(3):106278. PubMed ID: 33434676
[TBL] [Abstract][Full Text] [Related]
18. Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.
Castón JJ; De la Torre Á; Ruiz-Camps I; Sorlí ML; Torres V; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956431
[TBL] [Abstract][Full Text] [Related]
19. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
[TBL] [Abstract][Full Text] [Related]
20. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
